Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence

Rhea-AI Summary

Klotho Neurosciences (Nasdaq: KLTO) announced that IP Australia has notified the company and its licensor, Universitat Autonoma de Barcelona, that 18 patent claims for composition and use of the human secreted Klotho protein (s-KL) isoform are to be granted.

The claims cover a muscle-cell specific promoter linked to an s-KL gene sequence for treating motor impairment, plus neuronal/iPSC cell uses and delivery systems including AAV and non-viral vectors with muscle or motor neuron tropism.

Positive

• 18 patent claims accepted by IP Australia
• Claims include muscle-cell promoter linked to s-KL gene sequence
• Claims cover AAV and non‑viral vector delivery systems
• Includes use in neuronal cells and iPSC with s-KL

Negative

• Patent action limited to Australia jurisdiction
• No clinical or financial results disclosed in this announcement

News Market Reaction – KLTO

+9.26% 1.8x vol

7 alerts

+9.26% News Effect

+15.1% Peak in 23 hr 40 min

+$1M Valuation Impact

$18M Market Cap

1.8x Rel. Volume

On the day this news was published, KLTO gained 9.26%, reflecting a notable positive market reaction. Argus tracked a peak move of +15.1% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $18M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patent claims granted: 18 claims

1 metrics

Patent claims granted 18 claims Accepted within Australian patent application for s-KL composition and use

Market Reality Check

Price: $0.2358 Vol: Volume 141,961 is at 0.26...

low vol

$0.2358 Last Close

Volume Volume 141,961 is at 0.26x the 20-day average of 536,019, indicating subdued trading ahead of this patent news. low

Technical Pre-news price 0.216 is trading below the 200-day MA of 0.61, reflecting a longer-term downtrend and positioning the stock far under prior levels.

Peers on Argus

KLTO’s -2.22% move contrasted with mixed biotech peers: IGC -8.57%, LSB -20.62%,...

KLTO’s -2.22% move contrasted with mixed biotech peers: IGC -8.57%, LSB -20.62%, LVTX -3.87% weaker, while JSPR +4.31% and MRSN +0.62% gained, suggesting stock-specific dynamics around this patent update rather than a clear sector-wide pattern.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Conference presentation	Positive	+1.2%	CEO scheduled to present at Biotech Showcase 2026 and meet investors.
Nov 07	Industry award	Positive	-3.2%	Company wins Cell Therapy Innovation of the Year for s-KL platform.
Oct 16	Conference attendance	Neutral	-6.3%	Management attending Longevity Biotech 2025 and pursuing collaborations.
Oct 07	Strategic shift	Positive	+14.3%	LOI with Turn Biotechnologies expires; focus shifts to Klotho pipeline.
Sep 30	LOI and partnership	Neutral	-4.2%	LOI to acquire Turn Biotechnologies assets and $300M partnership rights.

Pattern Detected

Recent KLTO news has produced mixed reactions: strategic or recognition-related updates sometimes aligned with positive price moves but have also seen negative or muted responses, indicating inconsistent trading around headlines.

Recent Company History

Over the past six months, KLTO has issued several strategic and visibility-focused updates. A Sept 30, 2025 LOI tied to a $300 million partnership saw a negative reaction, while its Oct 7, 2025 decision to let that LOI expire and refocus on Klotho programs was followed by a 14.27% gain. Conference and showcase participation in Oct 2025 and Jan 2026 produced modest, mixed moves. Against this backdrop, today’s Australian patent claims expand the same Klotho-based therapeutic platform.

Market Pulse Summary

The stock moved +9.3% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +9.3% in the session following this news. A strong positive reaction aligns with the strategic importance of securing 18 composition and use claims for the s-KL platform in Australia, strengthening KLTO’s intellectual property around neuromuscular and motor neuron indications. However, historical filings highlight ongoing losses and going-concern risks, and recent news has not always produced sustained gains. Investors would need to weigh IP expansion against financing needs and Nasdaq compliance constraints.

Key Terms

induced pluripotent stem cells, iPSC, adeno-associated viral vectors, amyotrophic lateral sclerosis, +4 more

8 terms

induced pluripotent stem cells medical

"The claims also cover the use of neuronal cells and induced pluripotent stem cells (iPSC)..."

Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, meaning they can become many different cell types. For investors, iPSCs matter because they are a flexible platform for developing new drugs, testing safety, and creating personalized therapies; think of them as blank building blocks that can be used to prototype treatments and reduce development risk before large clinical bets.

iPSC medical

"induced pluripotent stem cells (iPSC) containing the muscle-cell specific promoter..."

Induced pluripotent stem cells (iPSCs) are ordinary adult cells that scientists have reprogrammed back into a versatile, embryonic-like state so they can become many different cell types. Think of them as factory-reset cells that can be turned into heart, nerve, or blood cells for testing drugs, modeling diseases, or developing cell therapies. For investors, iPSCs signal potential high-reward opportunities in new treatments and research tools but also carry technical, manufacturing and regulatory risks that affect commercial prospects.

adeno-associated viral vectors medical

"other cellular delivery systems such as adeno-associated viral vectors or "AAV")..."

Adeno-associated viral (AAV) vectors are harmless, engineered viruses used as microscopic delivery trucks to carry corrective genetic instructions into a patient’s cells. Investors care because AAV-based therapies can potentially provide long-lasting cures for inherited or chronic diseases, creating large commercial opportunities, but they also bring regulatory scrutiny, high development and manufacturing costs, and safety and durability uncertainties that affect a therapy’s market value and risk profile.

amyotrophic lateral sclerosis medical

"Neuromuscular diseases include amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease..."

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

muscular dystrophy medical

"multiple sclerosis, muscular dystrophy (both Duchenne and Becker muscular dystrophy)..."

Muscular dystrophy is a group of inherited conditions that progressively weaken and break down skeletal muscles, making everyday movements harder over time; think of muscle fibers like ropes that gradually fray and lose strength. It matters to investors because the chronic, often long-term nature of these diseases creates clear demand for drugs, gene therapies and supportive care, shaping clinical trial activity, regulatory attention, market size and potential returns — as well as reimbursement and pricing debates.

spinal muscular atrophy medical

"Specific motor neuron disorders or 'MND' include ALS, progressive bulbar palsy... SMA, or monomelic amyotrophy..."

A genetic condition in which the “wiring” between the spinal cord and muscles fails, causing progressive loss of muscle strength and motor skills from infancy through adulthood as the nerve cells that move muscles deteriorate. Investors pay attention because the condition creates a clear, long-term need for specialized therapies, diagnostics and ongoing care — meaning successful drugs or tests can attract premium pricing, sustained demand and significant regulatory and reimbursement scrutiny that materially affect biotech and healthcare valuations.

peripheral neuropathy medical

"myositis, peripheral neuropathy, neuromyotonia, Lambert-Eaton disease..."

A condition where nerves outside the brain and spinal cord are damaged, causing numbness, tingling, pain or weakness—like faulty wiring that sends mixed or dropped signals between the brain and parts of the body. Investors watch it because it drives demand for drugs, medical devices and diagnostics, shapes clinical trial results and regulatory decisions, and can influence healthcare costs, company revenues and legal risk in related industries.

acute inflammatory demyelinating polyradiculoneuropathy medical

"autoimmune peripheral polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (AIDP)..."

A condition in which the body's immune system mistakenly attacks the insulation (myelin) around peripheral nerves, causing rapid muscle weakness, numbness, and sometimes paralysis that can require hospitalization and long recovery. For investors, it matters because cases can affect clinical trial safety assessments, regulatory reviews, product liability or demand for treatments, and workforce availability—similar to how a sudden factory shutdown from an illness can disrupt operations and costs.

AI-generated analysis. Not financial advice.

NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the Company) announces the acceptance of 18 claims within a patent application filed in Australia for composition and use of human secreted Klotho protein ("s-KL") isoform of the human gene sequence. The Australian government entity IP Australia has notified the Company and the licensor of the technology, Universitat Autonoma de Barcelona, that these claims are to be granted. The 18 claims cover the use of a human muscle-cell specific promoter operatively linked to a nucleic acid gene sequence encoding human the human s-KL protein for treating motor impairment. The claims also cover the use of neuronal cells and induced pluripotent stem cells (iPSC) containing the muscle-cell specific promoter and s-KL nucleic acid gene sequence encoding human the human s-KL protein and other cellular delivery systems such as adeno-associated viral vectors or "AAV") or non-viral vectors with muscle-cell and/or motor neuron-cell tropism.

Dr. Joseph Sinkule, founder and CEO of KLTO stated, "These claims are an important expansion of our patent estate, which we believe will help to provide momentum and security to pursue the therapeutic replacement or supplementation of human Klotho levels. As people age, they naturally lose innate, in vivo therapeutic concentrations of Klotho due to the commonly occuring DNA methylation of the promoter and gene leading to the 'silencing' of the Klotho gene in neuromuscular ('motor neuron') cells and tissues in our body. The 'method of use' component of these claims includes treatment, wherein the subject has a disease or disorder characterized by motor impairment, such as a neuromuscular or motor neuron disease. We believe our approach to utilizing s-KL protein is a significant innovation and we look forward to continuing to develop our capabilities around addressing Klotho supplementation, and to providing updates as they emerge."

Neuromuscular diseases include amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease, multiple sclerosis, muscular dystrophy (both Duchenne and Becker muscular dystrophy), myasthenia gravis, myopathy, myositis, peripheral neuropathy, neuromyotonia, Lambert-Eaton disease, Friedreich's ataxia, traumatic nerve injury, diabetic neuropathy, motor skills disorder, spinal muscular atrophy (SMA), spinal cord injury, peripheral nerve injury, traumatic nerve injury, hereditary myopathy, toxic neuropathy, autoimmune peripheral polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropahty (CIDP), drug-induced myopathy, sarcopenia, cachexia, age-related muscular atrophy, type II muscle fiber atrophy, or an acquired autoimmune primary muscle disorder. Specific motor neuron disorders or 'MND' include ALS, progressive bulbar palsy (PBP), pseudobulbar palsy, progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), SMA, or monomelic amyotrophy (MMA).

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a gene and cell therapy company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from the "anti-aging" human Klotho gene (s-KL), tissue-specific promoters, and novel tissue and organ delivery systems to transform and improve the treatment of neurodegenerative disorders such as ALS, Alzheimer's disease, Parkinson's disease and age-related neuronal, ocular, skeletal and muscular pathologies.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Contact and Corporate Communications:

Jeffrey LeBlanc, CFO
ir@klothoneuro.com
Website: www.klothoneuro.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-receives-patent-claims-in-australia-for-composition-and-use-of-human-secreted-klotho-protein-s-kl-isoform-of-the-human-klotho-gene-sequence-302689861.html

SOURCE Klotho Neurosciences, Inc.

FAQ

What did KLTO announce about patents in Australia on February 18, 2026?

KLTO said IP Australia notified that 18 claims will be granted for s-KL composition and use. According to the company, the claims cover promoters, gene sequences, cell types, and delivery systems including AAV and non‑viral vectors.

What therapeutic uses do the new KLTO patent claims cover for s-KL (KLTO)?

The claims cover treating subjects with diseases featuring motor impairment using s-KL. According to the company, this includes neuromuscular and motor neuron disorders such as ALS, SMA, muscular dystrophy, and related conditions.

Which delivery methods are included in KLTO's accepted patent claims in Australia?

The accepted claims include cellular and vector delivery systems such as AAV and non‑viral vectors with muscle or motor neuron tropism. According to the company, neuronal cells and iPSC containing the constructs are also covered.

Does the KLTO patent acceptance in Australia protect global rights to s-KL therapies?

No, the notice pertains to a patent application in Australia and its 18 claims to be granted there. According to the company, the notification came from IP Australia and involves the Australian patent application specifically.

How might KLTO's Australian patent claims affect its intellectual property position (KLTO)?

The company said the claims expand its patent estate and could provide momentum and security for s-KL development. According to the company, this strengthens IP around muscle‑cell promoters, s‑KL sequences, and delivery modalities in Australia.